Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.46 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8863562 | 0.86 | GAA (0.49) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL21410215 | 0.83 | CA2 (0.51) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL2871473 | 0.83 | HSP90AA1 (0.43) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL23113418 | 0.83 | HTT (0.42) | ALDH1A1TSHRLMNACA2CA5A | |
| Bromide SCHEMBL25295782 | 0.82 | CA2 (0.50) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL816810 | 0.82 | HTT (0.48) | ALDH1A1TSHRLMNACA2CA5A | |
| SCHEMBL2214769 | 0.82 | CYP19A1 (0.52) | ALDH1A1CYP3A4TSHRLMNACA2 | |
| SCHEMBL1005841 | 0.80 | TSHR (0.55) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL1996062 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL67742 | 0.80 | CES2 (0.48) | ALDH1A1CYP3A4HPGDALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
| EP-3793996-A1 | KINASE INHIBITORS | The University of Manchester (GB) | 2021-03-24 | — | — | EP | disclosed |
| CN-112119077-A | Kinase inhibitors | 曼彻斯特大学 | 2020-12-22 | — | — | CN | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| CN-107250110-B | Novel compounds as inhibitors of transfection Rearrangement (RET) | 葛兰素史克知识产权发展有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| EP-3191449-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016037578-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | RET, FER, THRB | ALDH1A1 2176/4885CYP3A4 2931/4885HPGD 3888/4885 |
| US-20170298074-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ALDH1A1 2779/4885CYP3A4 3203/4885HPGD 3925/4885 |
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | ALDH1A1 2394/4885CYP3A4 3794/4885HPGD 1397/4885 |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ALDH1A1 2779/4885CYP3A4 3203/4885HPGD 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.